ABVIRO LLC

ABVIRO LLC specializes in the research, development, and clinical evaluation of novel monoclonal antibody therapeutics for infectious disease indications, with a demonstrated focus on dengue virus immunotherapy. The company’s core capabilities center on translational biotechnology, including the design, preclinical optimization, and human challenge trial execution of high-affinity neutralizing antibodies. Their technical expertise spans antibody engineering, virology, clinical trial design for human challenge models, and regulatory pathway development for biologics under FDA oversight. A key differentiator is their targeted approach to developing injectable therapeutics for acute viral pathogens, leveraging human challenge platforms to accelerate efficacy assessment and dose optimization—bridging the gap between laboratory discovery and clinical validation. ABVIRO has established a consistent relationship with the Department of Health and Human Services, delivering contract research services focused on biodefense and emerging infectious disease therapeutics. Their work with HHS has centered on advancing monoclonal antibody candidates from early-stage development through Phase 2 clinical evaluation, indicating a trusted partnership in public health preparedness and biomedical innovation. The company operates primarily within NAICS 541711 (biotechnology R&D) and 541715 (life sciences R&D), reflecting a narrow but deep specialization in antibody-based therapeutics and human clinical testing for viral pathogens. This positions ABVIRO as a niche provider in the biopharmaceutical R&D sector, serving government-funded initiatives focused on pandemic response and countermeasure development. ABVIRO LLC is a small business entity based in Bethesda, Maryland, with no federal certifications on record. Its geographic proximity to federal research institutions and regulatory agencies enhances its ability to collaborate on federally funded biomedical projects, reinforcing its role as a specialized contractor in the U.S. government’s infectious disease therapeutics ecosystem.